Guideline No. 444: Hirsutism: Evaluation and Treatment

医学 指南 多毛症 梅德林 妇科 医学物理学 内科学 病理 政治学 法学 胰岛素抵抗 胰岛素 多囊卵巢
作者
Jason Elliott,Kimberly Liu,Tarek Motan
出处
期刊:Journal of obstetrics and gynaecology Canada [Elsevier BV]
卷期号:45 (12): 102272-102272 被引量:3
标识
DOI:10.1016/j.jogc.2023.102272
摘要

Abstract

Objective

This guideline reviews the etiology, diagnosis, evaluation, and treatment of hirsutism.

Target Population

Women with hirsutism.

Options

Three approaches to management include: 1) mechanical hair removal; 2) suppression of androgen production; and 3) androgen receptor blockade.

Outcomes

The main limitations of the management options include the adverse effects, costs, and duration of treatment.

Benefits, Harms, and Costs

Implementation of the recommendations in this guideline may improve the management of hirsutism in women with this condition. Adverse effects and a potential long duration of treatment are the main drawbacks to initiating treatment, as is the possibility of significant financial costs for certain treatments.

Evidence

A comprehensive literature review was updated to April 2022, following the same methods as for the prior Society of Obstetricians and Gynaecologists of Canada (SOGC) Hirsutism guidelines. Results were restricted to systematic reviews, randomized controlled trials, controlled clinical trials, and observational studies. There were no date limits, but results were limited to English- or French-language materials.

Validation Methods

The authors rated the quality of evidence and strength of recommendations using the modified Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, along with the option of designating a recommendation as a "good practice point." See online Appendix A (Tables A1 for definitions and A2 for interpretations of strong and conditional [weak] recommendations).

Intended Audience

Primary care providers, family medicine physicians, obstetricians and gynaecologists, reproductive endocrinologists and others who manage the care of patients with hirsutism.

Tweetable Abstract

Management of hirsutism involves a 3-pronged approach of mechanical hair removal, suppression of androgen production, and androgen receptor blockade.

SUMMARY STATEMENTS

  • 1.The modified Ferriman-Gallwey score can be used in the assessment of hirsutism to help quantify the problem and assess the response to treatment. Cut-off scores defining hirsutism will vary by racial background. Modified Ferriman-Gallwey scores from 3 to 15 represent mild hirsutism, 16–25 represent moderate hirsutism, and >25 indicate severe hirsutism (moderate).
  • 2.Hyperandrogenism in women with polycystic ovary syndrome may result from several mechanisms, including insulin resistance, hyperinsulinemia, elevated luteinizing hormone–related increases in theca cell androgen production, and increased adrenal androgen output. (high).
  • 3.Non-classical congenital adrenal hyperplasia often presents with hirsutism and has a similar clinical picture as polycystic ovary syndrome. However, the prevalence of non-classical congenital adrenal hyperplasia is very low outside of specific high-risk ethnic groups (high).
  • 4.Hirsutism can be classified into 1 of 3 groups based on etiology: hyperandrogenic hirsutism (including polycystic ovarian syndrome, non-classical congenital adrenal hyperplasia, or androgen-secreting tumours), non-androgenic hirsutism (including medication-induced hirsutism), and idiopathic hirsutism (moderate).
  • 5.Polycystic ovary syndrome is the most common cause of hirsutism, with idiopathic hirsutism being the second most common (high).
  • 6.Most patients with hirsutism have normal androgen levels. That said, high androgen levels should be investigated immediately, as some impacts will be permanent, such as voice changes and clitoromegaly (high).
  • 7.Hirsutism is not a diagnosis, but a symptom or sign, and an underlying etiology should be sought (high).
  • 8.The most effective therapy for hirsutism is multimodal and combines physical hair removal techniques with medical therapies. At least six months of medical therapy is required to see a significant improvement in hirsutism. Unfortunately, many permanent physical hair removal procedures are considered cosmetic and the costs can be a barrier to treatment (moderate).
  • 9.Hair growth tends to recur after stopping medical therapy, while laser hair removal, intense pulsed light, and electrolysis produce permanent hair reduction (moderate).

RECOMMENDATIONS

  • 1.Patients presenting with hirsutism should be evaluated with a focused history taking, physical examination with anthropometric measurements, and appropriate investigations to differentiate between the possible etiologies (strong, moderate).
  • 2.Patients with moderate to severe hirsutism should undergo blood testing to determine total testosterone and sex hormone–binding globulin levels; however, the benefit of testing in mild hirsutism is questionable. Additional testing is indicated for patients with irregular cycles and signs of hyperandrogenism or other endocrinopathies (conditional, low).
  • 3.Patients with hyperandrogenic hirsutism should have serum levels of dehydroepiandrosterone sulfate and 17-hydroxyprogesterone measured (strong, moderate).
  • 4.Referral for evaluation by a medical or reproductive endocrinologist (or another practitioner with similar expertise) is indicated in the presence of 1) virilization; 2) serum testosterone or dehydroepiandrosterone sulfate levels more than twice the upper limit of normal; 3) signs or symptoms of Cushing syndrome; or 4) early follicular phase serum 17-hydroxyprogesterone levels >6 nmol/L (strong, high).
  • 5.Therapy should be offered to all patients with hirsutism who desire treatment (good practice point).
  • 6.Combined hormonal contraceptives should be offered as first-line therapy if there are no contraindications (strong, high).
  • 7.Mechanical hair removal and/or topical treatments can be offered as first-line therapy or as an adjuvant to medical therapy (strong, high).
  • 8.Antiandrogens can be considered as monotherapy or in addition to combined hormonal contraceptives to enhance efficacy (strong, high).
  • 9.Patients on antiandrogens require an effective method of contraception and should be counselled regarding the risk of feminization of a male fetus if pregnancy were to occur (good practice point).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Orange应助禹宛白采纳,获得10
1秒前
打打应助醉蓝采纳,获得10
1秒前
哈哈哈哈哈完成签到,获得积分10
2秒前
Wu发布了新的文献求助10
2秒前
昏睡的蟠桃应助Polymer72采纳,获得50
2秒前
黄桃发布了新的文献求助10
2秒前
Weimiao完成签到,获得积分10
2秒前
2秒前
3秒前
4秒前
解洙发布了新的文献求助10
4秒前
4秒前
MIN发布了新的文献求助10
4秒前
5秒前
mys发布了新的文献求助10
6秒前
6秒前
Jim发布了新的文献求助10
6秒前
天天快乐应助dshihb采纳,获得10
6秒前
kari发布了新的文献求助10
7秒前
樱铃完成签到,获得积分10
7秒前
一安发布了新的文献求助10
8秒前
8秒前
惠1完成签到,获得积分10
8秒前
butter发布了新的文献求助10
8秒前
9秒前
9秒前
橘子完成签到,获得积分10
9秒前
元谷雪发布了新的文献求助10
9秒前
10秒前
10秒前
10秒前
10秒前
禾目香完成签到,获得积分10
10秒前
10秒前
李爱国应助路人甲采纳,获得10
11秒前
11秒前
苹果发布了新的文献求助10
11秒前
丘比特应助无奈夏菡采纳,获得10
11秒前
醉蓝完成签到,获得积分10
11秒前
111完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Organic Reactions, Volume 116 1500
VALIDATION OF THE TAYLOR, ALAMEL AND VPSC MODELS FOR PLASTIC ANISOTROPY MODELING OF SHEET METALS 1000
Geist der Kunst und Kultur 1000
Resistance Spot Welding Dataset for Automobile Body-in-White Quality Analysis 748
悉尼大学博士学位论文,题目:Modelling and testing of one-sided stitched laminated composites. 作者:Kristopher P. Plain 700
Machine Learning for Asset Management and Pricing 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7404809
求助须知:如何正确求助?哪些是违规求助? 9009511
关于积分的说明 19185860
捐赠科研通 7038269
什么是DOI,文献DOI怎么找? 3231887
关于科研通互助平台的介绍 2394147
邀请新用户注册赠送积分活动 2213858